The global response to the COVID-19 pandemic has centered on precise and reliable detection of SARS-CoV-2 infection. For developers of in vitro diagnostic (IVD) assays, understanding SARS-CoV-2 markers—viral components and host responses measurable in clinical specimens—is foundational to effective test design, validation, and regulatory compliance. As a specialized provider of key raw materials and biomarkers for IVD applications, Alfa Chemistry supports diagnostic innovators with a broad catalog of high-quality SARS-CoV-2 biomarkers and reagents tailored for antigen, nucleic acid, and serological assay workflows.
What Are SARS-CoV-2 Markers?
SARS-CoV-2 markers are measurable biological molecules associated with the virus or the host's response to infection. These markers serve as analytical targets in diagnostic assays that confirm the presence of the virus, quantify immune responses, or stratify disease severity.
Figure 1. COVID-19 biomarkers according to the organ or system involved[1].
In practice, markers fall into several key categories:
- Viral Genetic Material (RNA) — Detected via nucleic acid amplification tests (NAATs) such as RT-PCR, which remain the gold standard for identifying active SARS-CoV-2 infection by targeting specific genomic regions of the virus.
- Viral Proteins (Antigens) — Structural proteins such as Spike (S) and Nucleocapsid (N) antigens are abundant viral components used in antigen detection assays. Quantifying these proteins directly in respiratory or blood samples indicates viral presence.
- Serological Markers (Antibodies) – Host-generated antibodies, including IgM, IgG, or total immunoglobulin responses to SARS-CoV-2 antigens, provide evidence of past exposure or vaccine-induced immunity.
- Host Response Biomarkers – Inflammatory factors such as cytokines (e.g., IL-6, TNF-α) and acute phase proteins (e.g., ferritin, C-reactive protein) rise during infection and correlate with disease severity, offering prognostic insights.
Figure 2. The structure, genome, and diagnostic targets of SARS-CoV-2[2].
Diagnostic Applications of SARS-CoV-2 Markers
- Active Infection Detection (RT-PCR & Antigen Assays)
Viral RNA remains the definitive marker for detecting active SARS-CoV-2 infection. RT-PCR platforms amplify targeted sequences of the viral genome to achieve high sensitivity and specificity, enabling early detection even at low viral loads. Rapid antigen assays detect structural proteins like S or N antigens directly in nasopharyngeal swabs or blood, providing quicker turnaround times suitable for point-of-care settings.
Key Viral Markers for Active Detection
| Marker | Diagnostic Role | Typical Assay Type |
| SARS-CoV-2 RNA | Primary evidence of infection | RT-PCR / NAAT |
| Nucleocapsid Antigen (N) | Viral presence & viral load proxy | Rapid antigen test / immunoassay |
| Spike Protein (S) | Alternative antigen target | Immunoassay / lateral flow |
Alfa Chemistry supplies recombinant SARS-CoV-2 Spike and Nucleocapsid proteins for use as calibration standards or assay controls in molecular and antigen tests.
- Serological Profiling (Antibody Detection)
Antibody markers indicate whether an individual has mounted an immune response to SARS-CoV-2 infection or vaccination. Assays targeting IgM or IgG antibodies against the spike receptor-binding domain (RBD) or full spike protein support epidemiological surveillance and assessment of immune status. Antibodies against the N antigen specifically suggest natural infection, since vaccines generally target the spike antigen.
Serological Markers and Their Clinical Significance
| Marker | Interpretation |
| Anti-Spike IgG | Previous infection or vaccination |
| Anti-Nucleocapsid IgG | Prior natural infection |
| Total Antibody (mix IgM/IgG) | General immune response |
- Prognostic and Host Response Markers
Beyond presence/absence markers, host response biomarkers reflect immunological and inflammatory dynamics during infection. Elevated cytokines such as IL-6, TNF-α, and IFN-γ are associated with severe COVID-19 and systemic inflammation, informing clinical prognosis and therapeutic monitoring. Elevated acute phase proteins like C-reactive protein and D-dimer have shown association with complications such as coagulopathy.
Figure 3. Serological-based immunoassay for anti-SARS-CoV-2 antibodies[3].
Why SARS-CoV-2 Markers Matter in IVD Development
Accurate, repeatable detection of SARS-CoV-2 markers is essential for:
- Regulatory compliance: Benchmarking assay performance using well-characterized markers.
- Assay sensitivity/specificity: Choosing the right molecular or protein target improves clinical accuracy.
- Clinical utility: Differentiating active infection from past exposure and prognostic risk.
With its comprehensive SARS-CoV-2 product portfolio—including recombinant proteins, antibodies, and host biomarkers—Alfa Chemistry provides the raw materials to accelerate assay development from research through commercialization.
Conclusion
As diagnostic science advances post-pandemic, SARS-CoV-2 markers will continue to underpin robust testing strategies. Whether your priority is early infection detection, immunological profiling, or disease stratification, a deep understanding of these biomarkers enables precision assay design that meets clinical and regulatory expectations. Through tailored solutions and in-depth product support, Alfa Chemistry empowers your team to innovate with confidence.
Welcome to our product page to explore a more comprehensive portfolio of SARS-CoV-2 biomarker reagents.
References
- Lesniak SWS, et al. Biomarkers for SARS-CoV-2 infection. A narrative review. Front Med (Lausanne). 2025, 12, 1563998.
- Ludwig RJ, et al. Mechanisms of Autoantibody-Induced Pathology. Front Immunol. 2017, 8, 603.
- Habli Z, et al. COVID-19 in-vitro Diagnostics: State-of-the-Art and Challenges for Rapid, Scalable, and High-Accuracy Screening. Front Bioeng Biotechnol. 2021, 8, 605702.
Please kindly note that our products and services are for research use only.
